Could precious metal hold the key to the next-gen of cancer treatments?0 comments

Posted on 30 Dec 2008 at 11:30am

A precious metal which has never before been used in a clinical setting is being developed as an anti-cancer agent by University of Warwick researchers.

The metal, osmium, is closely related to platinum, which is widely used to treat cancers in the form of the drug cisplatin. Most famously, the cyclist Lance Armstrong was treated with cisplatin for testicular cancer. Now the researchers are working closely with Warwick Ventures, the University of Warwick’s technology transfer office, to seek partners to help develop the potential of osmium through more extensive biological tests.

Professor Pete Sadler, from the University of Warwick explained: “Although cisplatin has been proven to be very successful with treatment; it is not useful for all kinds of cancer. It is also quite a toxic therapy, which can produce side effects and, from a clinical point of view, cells can also become quite resistant to platinum.”

Osmium, with its special chemical properties, offers a new potential solution to an unmet clinical need. It has shown huge promise in treating several different types of cancer cell, including ovarian and colon cancers which have been developed and tested in the laboratory. The metal also has another advantage in that it is a much cheaper alternative to platinum.

Professor Sadler, along with post-graduate researcher Sabine van Rijt, is working to develop new compounds using Osmium, which they hope will lead to the development of drugs which could be used in combination therapies alongside existing drugs such as cisplatin.

van Rijt explained: “The compounds we have been developing are very promising. We’re building a picture of how different compounds might interact with DNA in cancer cells. By making changes to the coating, or ligand, on the metal, we can also affect not just how it interacts, but the rate of interaction.

“During this design process we can make changes which can control the activity of the compound.”

van Rijit continued: “Another advantage is that these compounds are not cross-resistant with platinum. They kill cancerous cells in a different way, so they could be used alongside platinum in combination therapies.”

Share:
  • Digg
  • del.icio.us
  • Technorati
  • Slashdot
  • Blue Dot
  • NewsVine
  • Reddit
  • StumbleUpon
  • Facebook
  • E-mail this story to a friend!
  • Fark
  • Google Bookmarks
  • Propeller


Read more on: , , , , ,
Also:

Leave a Reply